학술논문
SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months–4 Years — New Vaccine Surveillance Network, United States, July 2022–September 2023.
Document Type
Article
Author
Tannis, Ayzsa; Englund, Janet A.; Perez, Ariana; Harker, Elizabeth J.; Staat, Mary Allen; Schlaudecker, Elizabeth P.; Halasa, Natasha B.; Stewart, Laura S.; Williams, John V.; Michaels, Marian G.; Selvarangan, Rangaraj; Schuster, Jennifer E.; Sahni, Leila C.; Boom, Julie A.; Weinberg, Geoffrey A.; Szilagyi, Peter G.; Clopper, Benjamin R.; Zhou, Yingtao; McMorrow, Meredith L.; Klein, Eileen J.
Source
Subject
*COVID-19 vaccines
*VACCINE effectiveness
*VACCINATION of children
*EMERGENCY medicine
*
*
*
Language
ISSN
0149-2195
Abstract
SARS-CoV-2 infection in young children is often mild or asymptomatic; however, some children are at risk for severe disease. Data describing the protective effectiveness of COVID-19 mRNA vaccines against COVID-19–associated emergency department (ED) visits and hospitalization in this population are limited. Data from the New Vaccine Surveillance Network, a prospective population-based surveillance system, were used to estimate vaccine effectiveness using a test-negative, casecontrol design and describe the epidemiology of SARS-CoV-2 in infants and children aged 6 months–4 years during July 1, 2022–September 30, 2023. Among 7,434 children included, 5% received a positive SARS-CoV-2 test result, and 95% received a negative test result; 86% were unvaccinated, 4% had received 1 dose of any vaccine product, and 10% had received ≥2 doses. When compared with receipt of no vaccines among children, receipt of ≥2 COVID-19 mRNA vaccine doses was 40% effective (95% CI = 8%–60%) in preventing ED visits and hospitalization. These findings support existing recommendations for COVID-19 vaccination of young children to reduce COVID-19–associated ED visits and hospitalization. [ABSTRACT FROM AUTHOR]